Amrita Krishnan, MD

home / authors / amrita-krishnan-md

Articles

Quadruplet Combination Therapies in Relapsed Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 6th 2023

Hana Safa, MD, shares data on quadruplet therapies in the treatment of relapsed multiple myeloma.

Strategies for Treatment of Multiple Myeloma at Late Relapse

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 6th 2023

The panel debates the options for treatment of late relapsed multiple myeloma.

Data Updates in the Treatment of Relapsed Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

January 30th 2023

Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.

Relapse in Multiple Myeloma: Biochemical and Chemical

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

January 30th 2023

Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.

Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

January 23rd 2023

Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.

Defining Frailty in Multiple Myeloma for Optimal Treatment

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

January 23rd 2023

Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.

Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

December 22nd 2022

Hana Safah, MD, explains the common treatment approaches for patients with transplant-ineligible multiple myeloma.

Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

December 22nd 2022

Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.

Dr. Krishnan of the Effectiveness of Teclistamab in Relapsed/Refractory Multiple Myeloma

Amrita Krishnan, MD

June 22nd 2022

Amrita Krishnan, MD, discusses the effectiveness of teclistamab in relapsed/refractory multiple myeloma.

Key Takeaways From the ASH 2021 Meeting on Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

Amrita Krishnan, MD

January 25th 2022

Closing out her discussion on the management of newly diagnosed and relapsed/refractory multiple myeloma, Amrita Y. Krishnan, MD, shares key takeaways from the ASH 2021 Annual Meeting.

How Will Bispecific Antibodies Fit Into the Multiple Myeloma Treatment Paradigm?

Amrita Krishnan, MD

January 25th 2022

Amrita Y. Krishnan, MD, considers where bispecific antibodies will fit into the multiple myeloma treatment paradigms as single-agent or combination therapy.

A Role for Bispecific Antibodies in R/R MM: Data From MonumenTAL-1 and MajesTEC-1 Studies

Amrita Krishnan, MD

January 25th 2022

Insight on results from the MonumenTAL-1 and MajesTEC-1 studies, which evaluated bispecific antibodies in patients with relapsed/refractory multiple myeloma.

Treatment Options for Patients With MM at First Relapse

Amrita Krishnan, MD

January 25th 2022

Expert perspective on the management of multiple myeloma at first relapse in the context of recent clinical data from the ASH 2021 Annual Meeting.

$Dr. Krishnan on Key Aspects of the ELOQUENT Trials in Relapsed/Refractory Multiple Myeloma$

Dr. Krishnan on Key Aspects of the ELOQUENT Trials in Relapsed/Refractory Multiple Myeloma

Amrita Krishnan, MD

September 11th 2019

Amrita Krishnan, MD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research and a professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, discusses key aspects of the phase III ELOQUENT-2 and -3 trials in relapsed/refractory multiple myeloma.

<1 2